Document registry — page 26
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Difficulty initiating or maintaining sleep with daytime consequences, assessed by polysomnography, actigraphy or validated questionnaires.
18 Oct 2024 -
Consultation on the draft monograph for Larazotide acetate, which the assessment committee released for public comment before ratification. The draft grades the…
16 Oct 2024 -
What is the relationship between the indications in which melanocortin receptor agonists have been evaluated and the uses under which they are supplied?
Low16 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result…
Very low16 Oct 2024 -
Peptides, SARMs, injectable oils and raw materials. Long-established synthesis operation.
15 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low15 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes randomising 616 participants over 52 weeks. Primary result…
Moderate14 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Oct 2024 -
In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on heart-failure events?
Moderate11 Oct 2024 -
Consultation on the draft of this network meta-analysis, which registers the question: Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an…
10 Oct 2024 -
Randomised crossover, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2024 -
Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the…
05 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low04 Oct 2024 -
Peptides, SARMs, injectable oils and raw materials.
03 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low02 Oct 2024 -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a…
26 Sep 2024 -
Consultation on the draft monograph for AOD-9604, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Sep 2024 -
Peptides, SARMs and raw materials. 350+ catalogue lines.
25 Sep 2024 -
Diagnostic accuracy study of Gonadorelin in gh axis over single test. Primary result: An established diagnostic stimulation test. The Institute records that the…
Moderate22 Sep 2024 -
Record of documents ratified in the 2024 Q3 assessment cycle.
18 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Single-arm open-label study of Thymalin in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 Sep 2024 -
What can be concluded from a development programme that was discontinued, and how should the Institute record it?
Moderate09 Sep 2024 -
Consultation on the draft monograph for Gonadorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
08 Sep 2024 -
Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every…
06 Sep 2024 -
Observational study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low06 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Sep 2024 -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered…
01 Sep 2024 -
Growth-hormone-releasing hormone analogue. Tesamorelin stimulates the pituitary to release endogenous growth hormone in a pulsatile pattern, preserving the physiological feedback architecture…
Moderate01 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low31 Aug 2024 -
Peptides, SARMs, injectable oils and raw materials.
28 Aug 2024 -
Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
27 Aug 2024 -
GLP-1 receptor agonist (acylated, once-daily). Receptor pharmacology is that of the selective GLP-1 class. The pharmacokinetic engineering differs: self-association into heptamers at the…
High27 Aug 2024 -
What is the evidence that glucagon-like peptide-1 receptor agonism increases the risk of medullary thyroid carcinoma in humans?
Low23 Aug 2024 -
Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.
21 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Aug 2024
page 26 of 41